Group 1 - A class action has been filed on behalf of investors who purchased PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024, and March 3, 2025 [1] - PepGen is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with its lead product candidate being PGN-EDO51 for Duchenne muscular dystrophy (DMD) [1] - Allegations against PepGen include misleading investors about the effectiveness and safety of PGN-EDO51, deficiencies in the CONNECT2 study, and overstated clinical and commercial prospects [2] Group 2 - On January 29, 2025, PepGen reported safety concerns in the CONNECT1 study and FDA concerns regarding the CONNECT2 study, leading to a stock price drop of $0.40 per share (21.74%) [3] - Following a press release on March 4, 2025, announcing a voluntary pause of the CONNECT2 study, PepGen's stock price fell by $0.53 per share (18.86%) [4] - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025 [5]

Core Viewpoint - A class action lawsuit has been filed against Vestis Corporation for allegedly misleading investors about customer growth and strategic initiatives [1][2]. Allegations - The complaint claims that Vestis Corporation did not disclose its inability to execute planned strategic initiatives aimed at improving customer experience and onboarding, which were expected to drive new customer growth and retention [2]. - It is alleged that these misleading statements led to investors purchasing Vestis securities at artificially inflated prices [2]. Financial Results and Market Reaction - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrew its revenue guidance for the full year, and provided third-quarter guidance that was significantly below market expectations [3]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in volume changes with existing customers [3]. - Following this announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in just one day [3]. Class Action Participation - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025, with the lead plaintiff representing other class members in the litigation [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. Company Background - Robbins LLP, the firm leading the class action, specializes in shareholder rights litigation and has been active in helping shareholders recover losses and improve corporate governance since 2002 [5].

Red Cat Holdings, Inc. (NASDAQ: RCAT) - Class action lawsuit initiated for stockholders covering the period from March 18, 2022, to January 15, 2025, with a lead plaintiff deadline of July 22, 2025 [2] - Allegations include misleading statements regarding the production capacity of Red Cat's Salt Lake City facility and the value of the Short Range Reconnaissance Program contract [3][4] - On July 27, 2023, Red Cat disclosed that its facility could only produce 100 drones per month, leading to a nearly 9% drop in stock price [4] - Financial results for Q1 FY2025 revealed losses per share of $0.17, missing estimates by $0.09, and revenue of $2.8 million, missing by $1.07 million, causing a more than 25% decline in stock price [5] - A report from Kerrisdale Capital on January 16, 2025, claimed the SRR contract was less favorable than previously indicated, resulting in a stock price drop of over 21% [6] Fortrea Holdings Inc. (NASDAQ: FTRE) - Class action lawsuit initiated for stockholders covering the period from July 3, 2023, to February 28, 2025, with a lead plaintiff deadline of August 1, 2025 [7] - Fortrea was spun off from Labcorp Holdings Inc. in June 2023, and entered into transition services agreements with Labcorp [7] - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a stock price drop of 25.05% [8] - Allegations include overestimating revenue from Pre-Spin projects and overstating cost savings from exiting TSAs, which inflated EBITDA targets and overstated the viability of the post-Spin-Off business model [9]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Red Cat Holdings, Inc. (NASDAQ: RCAT) securities during the specified period, alleging that the company misled investors regarding its production capacity and the value of its contracts [1][2]. Allegations - The complaint asserts that Red Cat Holdings failed to disclose that the production capacity of its Salt Lake City Facility was overstated and that the value of the U.S. Army's Short Range Reconnaissance Program (SRR) Contract was also exaggerated [2]. - Kerrisdale Capital's report indicated that the SRR Contract was valued between $20 million and $25 million, contrary to Red Cat's claims, and raised concerns about misleading information regarding the Salt Lake City Facility's production capacity [3]. Stock Impact - Following the release of Kerrisdale Capital's report on January 16, 2025, Red Cat's stock price dropped by $2.35 per share, representing a decline of 21.54%, closing at $8.56 per share on January 17, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action have until July 22, 2025, to apply for this status, although participation is not required to be eligible for recovery [4]. Company Background - Robbins LLP has been recognized for its efforts in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against Iovance Biotherapeutics - The complaint states that Iovance failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to begin treating patients with Amtagvi [2]. - It is alleged that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-offs [2]. - These issues led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, making the company's positive statements about its business misleading [2]. Group 2: Financial Performance - On May 8, 2025, Iovance reported a quarterly total product revenue of $49.3 million, down from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated forecast was attributed to recent launch dynamics of Amtagvi and the growth trajectories and treatment timelines for new ATCs [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action has been filed against Canopy Growth Corporation for allegedly misleading investors regarding its cost reduction measures and financial performance during a specific period [1][2]. Allegations - The complaint alleges that Canopy Growth Corporation failed to disclose significant costs associated with the production of Claybourne pre-rolled joints and indirect costs related to Storz & Bickel vaporizer devices, which negatively impacted gross margins and overall financial results [2]. - It is claimed that the company overstated the effectiveness of its cost reduction measures while downplaying issues related to gross margins [2]. Financial Impact - On February 7, 2025, Canopy announced disappointing financial results attributed to the costs from the Claybourne product launch and increased indirect costs, leading to a 27.24% drop in share price, closing at $2.02 [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Canopy Growth Corporation, with a deadline to contact Robbins LLP by June 3, 2025, for those wishing to serve as lead plaintiff [4]. Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased NET Power Inc. securities between June 9, 2023, and March 7, 2025, alleging that the company misled investors regarding the timeline and costs associated with Project Permian [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that NET Power failed to disclose that Project Permian was unlikely to be completed on schedule and would incur significantly higher costs due to supply chain issues and site-specific challenges [2]. - Following the announcement of third quarter 2023 results, NET Power's stock fell over 18% after revealing a 12-month delay in the project timeline, now expecting initial power generation between the second half of 2027 and first half of 2028 [3]. - On March 10, 2025, NET Power disclosed that the total installed cost for Project Permian is now estimated to be between $1.7 billion and $2.0 billion, a significant increase from the previous estimate of $1.1 billion, and announced a further delay to no earlier than 2029, causing the stock price to drop over 31% [4]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by June 17, 2025, although participation is not required to be eligible for recovery [5].

Group 1 - A class action has been filed on behalf of investors who purchased Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022, and January 15, 2025 [1] - The allegations include that Red Cat Holdings misled investors regarding its production capacity at the Salt Lake City Facility and overstated the value of the SRR Contract [2] - Kerrisdale Capital reported that the SRR Contract was valued between $20 million and $25 million, significantly lower than previously stated, leading to a 21.54% drop in Red Cat's stock price [3] Group 2 - Shareholders interested in serving as lead plaintiff have until July 22, 2025, to seek this status in the class action [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5]

Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for allegedly misleading investors about its production capacity and the value of its contracts, particularly the SRR Contract with the U.S. Army [1][2][3]. Group 1: Allegations and Complaints - The lawsuit claims that Red Cat Holdings overstated the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [2]. - Kerrisdale Capital's report indicated that the SRR Contract was valued between $20 million to $25 million, contrary to Red Cat's claims, leading to a significant drop in stock price [3]. Group 2: Stockholder Information - Shareholders interested in participating as lead plaintiffs have until July 22, 2025, to seek this status, while those who do not wish to participate can remain as absent class members [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [5].

Core Viewpoint - A class action lawsuit has been filed against Napco Security Technologies, Inc. for allegedly misleading investors about its growth projections and sales performance during the fiscal year 2025 [1][2]. Allegations - The lawsuit claims that Napco failed to disclose its true ability to forecast product demand and its negotiating position with distributors, leading to inflated long-term growth projections [2]. - Napco attributed its declining hardware sales to one-off setbacks, while the complaint suggests that the company's forecasting processes were inadequate [2]. Financial Impact - On February 3, 2025, Napco reported disappointing financial results for Q2 of fiscal 2025, showing a significant drop in hardware sales [3]. - Following this announcement, Napco's stock price fell from $36.70 per share on January 31, 2024, to $26.93 per share on February 3, 2025, marking a decline of approximately 26.62% in one day [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by June 24, 2025, but participation is not required to be eligible for recovery [4]. - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [5].